Literature DB >> 27161890

Activity of daily living for Morquio A syndrome.

Eriko Yasuda1, Yasuyuki Suzuki2, Tsutomu Shimada3, Kazuki Sawamoto4, William G Mackenzie4, Mary C Theroux4, Christian Pizarro4, Li Xie4, Freeman Miller4, Tariq Rahman4, Heidi H Kecskemethy4, Kyoko Nagao4, Thierry Morlet4, Thomas H Shaffer4, Yasutsugu Chinen5, Hiromasa Yabe6, Akemi Tanaka7, Haruo Shintaku7, Kenji E Orii8, Koji O Orii8, Robert W Mason4, Adriana M Montaño9, Toshiyuki Fukao8, Tadao Orii10, Shunji Tomatsu11.   

Abstract

The aim of this study was to evaluate the activity of daily living (ADL) and surgical interventions in patients with mucopolysaccharidosis IVA (MPS IVA). The factor(s) that affect ADL are age, clinical phenotypes, surgical interventions, therapeutic effect, and body mass index. The ADL questionnaire comprises three domains: "Movement," "Movement with cognition," and "Cognition." Each domain has four subcategories rated on a 5-point scale based on the level of assistance. The questionnaire was collected from 145 healthy controls and 82 patients with MPS IVA. The patient cohort consisted of 63 severe and 17 attenuated phenotypes (2 were undefined); 4 patients treated with hematopoietic stem cell transplantation (HSCT), 33 patients treated with enzyme replacement therapy (ERT) for more than a year, and 45 untreated patients. MPS IVA patients show a decline in ADL scores after 10years of age. Patients with a severe phenotype have a lower ADL score than healthy control subjects, and lower scores than patients with an attenuated phenotype in domains of "Movement" and "Movement with cognition." Patients, who underwent HSCT and were followed up for over 10years, had higher ADL scores and fewer surgical interventions than untreated patients. ADL scores for ERT patients (2.5years follow-up on average) were similar with the-age-matched controls below 10years of age, but declined in older patients. Surgical frequency was higher for severe phenotypic patients than attenuated ones. Surgical frequency for patients treated with ERT was not decreased compared to untreated patients. In conclusion, we have shown the utility of the proposed ADL questionnaire and frequency of surgical interventions in patients with MPS IVA to evaluate the clinical severity and therapeutic efficacy compared with age-matched controls.
Copyright © 2016. Published by Elsevier Inc.

Entities:  

Keywords:  ADL; ERT; HSCT; MPS IVA; Surgical intervention

Mesh:

Year:  2016        PMID: 27161890      PMCID: PMC5016714          DOI: 10.1016/j.ymgme.2016.04.005

Source DB:  PubMed          Journal:  Mol Genet Metab        ISSN: 1096-7192            Impact factor:   4.797


  73 in total

1.  Orthopedic complications of overweight in children and adolescents.

Authors:  Erica D Taylor; Kelly R Theim; Margaret C Mirch; Samareh Ghorbani; Marian Tanofsky-Kraff; Diane C Adler-Wailes; Sheila Brady; James C Reynolds; Karim A Calis; Jack A Yanovski
Journal:  Pediatrics       Date:  2006-06       Impact factor: 7.124

2.  Anesthetic care and perioperative complications of children with Morquio syndrome.

Authors:  Mary C Theroux; Tanvi Nerker; Colleen Ditro; William G Mackenzie
Journal:  Paediatr Anaesth       Date:  2012-06-27       Impact factor: 2.556

3.  The lower extremity in Morquio syndrome.

Authors:  Arjun A Dhawale; Mihir M Thacker; Mohan V Belthur; Kenneth Rogers; Michael B Bober; William G Mackenzie
Journal:  J Pediatr Orthop       Date:  2012 Jul-Aug       Impact factor: 2.324

4.  Umbilical cord blood transplantation for Maroteaux-Lamy syndrome (mucopolysaccharidosis type VI).

Authors:  V Lee; C K Li; M M Shing; K W Chik; C W Lam; K S Tsang; H Pong; K F Huen; P M Yuen
Journal:  Bone Marrow Transplant       Date:  2000-08       Impact factor: 5.483

5.  Abnormal mandibular growth after craniovertebral surgery in Morquio syndrome type A.

Authors:  Efisio Defraia; Andrea Marinelli; Antonino Antonini; Veronica Giuntini
Journal:  Angle Orthod       Date:  2005-05       Impact factor: 2.079

6.  Improved metabolic correction in patients with lysosomal storage disease treated with hematopoietic stem cell transplant compared with enzyme replacement therapy.

Authors:  Robert F Wynn; J Ed Wraith; Jean Mercer; Anne O'Meara; Karen Tylee; Margaret Thornley; Heather J Church; Brian W Bigger
Journal:  J Pediatr       Date:  2009-04       Impact factor: 4.406

7.  Current and emerging management options for patients with Morquio A syndrome.

Authors:  Mohamed F Algahim; G Hossein Almassi
Journal:  Ther Clin Risk Manag       Date:  2013-02-11       Impact factor: 2.423

Review 8.  International guidelines for the management and treatment of Morquio A syndrome.

Authors:  Christian J Hendriksz; Kenneth I Berger; Roberto Giugliani; Paul Harmatz; Christoph Kampmann; William G Mackenzie; Julian Raiman; Martha Solano Villarreal; Ravi Savarirayan
Journal:  Am J Med Genet A       Date:  2014-10-24       Impact factor: 2.802

9.  Molecular Genetics and Metabolism Report Long-term follow-up of post hematopoietic stem cell transplantation for Hurler syndrome: clinical, biochemical, and pathological improvements.

Authors:  Eriko Yasuda; William Mackenzie; Kristen Ruhnke; Tsutomu Shimada; Robert W Mason; Jozef Zustin; Paul L Martin; Mihir Thacker; Tadao Orii; Yoshimichi Sai; Shunji Tomatsu
Journal:  Mol Genet Metab Rep       Date:  2015-03

10.  Orthopedic management of the extremities in patients with Morquio A syndrome.

Authors:  Klane K White; Andrea Jester; C Edward Bache; Paul R Harmatz; Renée Shediac; Mihir M Thacker; William G Mackenzie
Journal:  J Child Orthop       Date:  2014-07-08       Impact factor: 1.548

View more
  15 in total

1.  Morquio Syndrome: A Case Report.

Authors:  Kamleshun Ramphul; Stephanie G Mejias; Yogeshwaree Ramphul-Sicharam
Journal:  Cureus       Date:  2018-03-05

Review 2.  Mucopolysaccharidosis IVA and glycosaminoglycans.

Authors:  Shaukat Khan; Carlos J Alméciga-Díaz; Kazuki Sawamoto; William G Mackenzie; Mary C Theroux; Christian Pizarro; Robert W Mason; Tadao Orii; Shunji Tomatsu
Journal:  Mol Genet Metab       Date:  2016-11-29       Impact factor: 4.797

3.  Effect of enzyme replacement therapy on the growth of patients with Morquio A.

Authors:  Caitlin Doherty; Molly Stapleton; Matthew Piechnik; Robert W Mason; William G Mackenzie; Seiji Yamaguchi; Hironori Kobayashi; Yasuyuki Suzuki; Shunji Tomatsu
Journal:  J Hum Genet       Date:  2019-04-24       Impact factor: 3.172

Review 4.  Molecular genetics and metabolism, special edition: Diagnosis, diagnosis and prognosis of Mucopolysaccharidosis IVA.

Authors:  Hira Peracha; Kazuki Sawamoto; Lauren Averill; Heidi Kecskemethy; Mary Theroux; Mihir Thacker; Kyoko Nagao; Christian Pizarro; William Mackenzie; Hironori Kobayashi; Seiji Yamaguchi; Yasuyuki Suzuki; Kenji Orii; Tadao Orii; Toshiyuki Fukao; Shunji Tomatsu
Journal:  Mol Genet Metab       Date:  2018-05-15       Impact factor: 4.797

5.  Non-invasive pulmonary function test on Morquio patients.

Authors:  Caitlin Doherty; Francyne Kubaski; Shunji Tomatsu; Thomas H Shaffer
Journal:  J Rare Dis Res Treat       Date:  2017

Review 6.  Bone-Specific Drug Delivery for Osteoporosis and Rare Skeletal Disorders.

Authors:  Kazuki Sawamoto; J Víctor Álvarez; Angélica María Herreño; Francisco J Otero-Espinar; Maria L Couce; Carlos J Alméciga-Díaz; Shunji Tomatsu
Journal:  Curr Osteoporos Rep       Date:  2020-10       Impact factor: 5.096

7.  Current therapies for Morquio A syndrome and their clinical outcomes.

Authors:  Kazuki Sawamoto; Yasuyuki Suzuki; William G Mackenzie; Mary C Theroux; Christian Pizarro; Hiromasa Yabe; Kenji E Orii; Robert W Mason; Tadao Orii; Shunji Tomatsu
Journal:  Expert Opin Orphan Drugs       Date:  2016-07-28       Impact factor: 0.694

8.  Liver-Targeted AAV8 Gene Therapy Ameliorates Skeletal and Cardiovascular Pathology in a Mucopolysaccharidosis IVA Murine Model.

Authors:  Kazuki Sawamoto; Subha Karumuthil-Melethil; Shaukat Khan; Molly Stapleton; Joseph T Bruder; Olivier Danos; Shunji Tomatsu
Journal:  Mol Ther Methods Clin Dev       Date:  2020-05-22       Impact factor: 6.698

9.  Morquio B patient/caregiver survey: First insight into the natural course of a rare GLB1 related condition.

Authors:  Maria Bleier; Nataliya Yuskiv; Tina Priest; Marioara Angela Moisa Popurs; Sylvia Stockler-Ipsiroglu
Journal:  Mol Genet Metab Rep       Date:  2018-07-20

10.  Neurophysiology of hearing in patients with mucopolysaccharidosis type IV.

Authors:  Kyoko Nagao; Thierry Morlet; Elizabeth Haley; Jennifer Padilla; Julianne Nemith; Robert W Mason; Shunji Tomatsu
Journal:  Mol Genet Metab       Date:  2018-02-08       Impact factor: 4.204

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.